BeiGene Ltd. will partner with Swiss firm Novartis AG to develop, manufacture and commercialize the China-based biotechnology company’s cancer drug tislelizumab.
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
French pharma giant Sanofi kicked off 2021 with a $1.4 billion cash acquisition of U.K.-based Kymab to bolster the company’s presence in immunology.
A small trial of Eli Lilly’s donanemab showed the experimental Alzheimer’s drug slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease.
A World Health Organization team of international experts tasked with investigating the origins of the Covid-19 pandemic will arrive in China on Jan. 14, Chinese authorities said.
Life sciences mergers and acquisitions (M&A) activity totaled $159 billion in 2020, down from $306 billion in 2019, reaching one of the lowest levels since 2014, according to the 2021 EY M&A Firepower report
Humanigen Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic Covid-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration and subsequent BLA.
Affinivax Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced the closing of a $226 million Series C financing.
DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.
Global health innovation leader W2O announced the acquisitions of tech-enabled companies Swoop and IPM.ai, further accelerating what is expected to be the company’s 20th consecutive year of double-digit revenue growth.
